Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for COVID-19 Associated Cytokine Release Syndrome
NCT04730323Phase 4Completed
- Sponsor
- FMH College of Medicine and Dentistry
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 4 trial of tocilizumab in coronavirus disease 2019 (COVID-19), sponsored by FMH College of Medicine and Dentistry. Started May 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04730323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730323.